Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
According to APO Research, The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Amylin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.
Glucagon Like Peptide-1 (GLP-1) Agonists segment by Company
1. To analyze and research the global Glucagon Like Peptide-1 (GLP-1) Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Glucagon Like Peptide-1 (GLP-1) Agonists market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Glucagon Like Peptide-1 (GLP-1) Agonists significant trends, drivers, influence factors in global and regions.
6. To analyze Glucagon Like Peptide-1 (GLP-1) Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Glucagon Like Peptide-1 (GLP-1) Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glucagon Like Peptide-1 (GLP-1) Agonists industry.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
According to APO Research, The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Glucagon Like Peptide-1 (GLP-1) Agonists is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Amylin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.
Glucagon Like Peptide-1 (GLP-1) Agonists segment by Company
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
- Hospital
- Pharmacy
- Other
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Glucagon Like Peptide-1 (GLP-1) Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Glucagon Like Peptide-1 (GLP-1) Agonists market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Glucagon Like Peptide-1 (GLP-1) Agonists significant trends, drivers, influence factors in global and regions.
6. To analyze Glucagon Like Peptide-1 (GLP-1) Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Glucagon Like Peptide-1 (GLP-1) Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glucagon Like Peptide-1 (GLP-1) Agonists industry.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Glucagon Like Peptide-1 (GLP-1) Agonists in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2019-2030)
1.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET DYNAMICS
2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY COMPANY
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2023
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2024)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (2019-2024)
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2019-2024)
3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Manufacturing Base & Headquarters
3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application
3.8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY TYPE
4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Type Introduction
4.1.1 Exenatied
4.1.2 Liraglutide
4.1.3 Lixisenatide
4.1.4 Albiglutide
4.1.5 Dulaglutide
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019-2030)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2030)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type
4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019-2030)
4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2030)
5 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY APPLICATION
5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Application Introduction
5.1.1 Hospital
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019-2030)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2030)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application
5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019-2030)
5.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2030)
6 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY REGION
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2030)
6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019-2024
6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030)
6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2030)
6.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019-2024
6.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030)
6.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.6.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.8.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.9.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.10.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
7 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY COUNTRY
7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
7.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024)
7.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030)
7.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2030)
7.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2024)
7.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.8.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.9.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.10.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.11.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.12.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.13.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.14.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.15.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.16.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.17.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.18.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.19.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.20.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.21.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.22.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.23.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Novo Nordisk
8.1.1 Novo Nordisk Comapny Information
8.1.2 Novo Nordisk Business Overview
8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.1.5 Novo Nordisk Recent Developments
8.2 AstraZeneca
8.2.1 AstraZeneca Comapny Information
8.2.2 AstraZeneca Business Overview
8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.2.5 AstraZeneca Recent Developments
8.3 Eli Lily
8.3.1 Eli Lily Comapny Information
8.3.2 Eli Lily Business Overview
8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.3.5 Eli Lily Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.4.5 GSK Recent Developments
8.5 Sanofi
8.5.1 Sanofi Comapny Information
8.5.2 Sanofi Business Overview
8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.5.5 Sanofi Recent Developments
8.6 Bristol-Myers Squibb
8.6.1 Bristol-Myers Squibb Comapny Information
8.6.2 Bristol-Myers Squibb Business Overview
8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.6.5 Bristol-Myers Squibb Recent Developments
8.7 Amylin
8.7.1 Amylin Comapny Information
8.7.2 Amylin Business Overview
8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.7.5 Amylin Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
9.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Mode & Process
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
9.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
1.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume (2019-2030)
1.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET DYNAMICS
2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY COMPANY
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2023
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2019-2024)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (2019-2024)
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2019-2024)
3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Manufacturing Base & Headquarters
3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application
3.8 Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY TYPE
4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Type Introduction
4.1.1 Exenatied
4.1.2 Liraglutide
4.1.3 Lixisenatide
4.1.4 Albiglutide
4.1.5 Dulaglutide
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019-2030)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2030)
4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type
4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019-2030)
4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2030)
5 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY APPLICATION
5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Application Introduction
5.1.1 Hospital
5.1.2 Pharmacy
5.1.3 Other
5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019-2030)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2030)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application
5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019-2030)
5.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2030)
6 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY REGION
6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2030)
6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019-2024
6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030)
6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2030)
6.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region: 2019-2024
6.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030)
6.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.6.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.7.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.8.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.9.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030)
6.10.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country, 2023 VS 2030
7 GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET BY COUNTRY
7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2030)
7.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024)
7.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030)
7.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2030)
7.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2024)
7.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.8.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.9.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.10.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.11.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.12.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.13.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.14.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.15.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.16.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.17.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.18.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.19.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.20.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.21.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.22.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
7.23.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Novo Nordisk
8.1.1 Novo Nordisk Comapny Information
8.1.2 Novo Nordisk Business Overview
8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.1.5 Novo Nordisk Recent Developments
8.2 AstraZeneca
8.2.1 AstraZeneca Comapny Information
8.2.2 AstraZeneca Business Overview
8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.2.5 AstraZeneca Recent Developments
8.3 Eli Lily
8.3.1 Eli Lily Comapny Information
8.3.2 Eli Lily Business Overview
8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.3.5 Eli Lily Recent Developments
8.4 GSK
8.4.1 GSK Comapny Information
8.4.2 GSK Business Overview
8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.4.5 GSK Recent Developments
8.5 Sanofi
8.5.1 Sanofi Comapny Information
8.5.2 Sanofi Business Overview
8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.5.5 Sanofi Recent Developments
8.6 Bristol-Myers Squibb
8.6.1 Bristol-Myers Squibb Comapny Information
8.6.2 Bristol-Myers Squibb Business Overview
8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.6.5 Bristol-Myers Squibb Recent Developments
8.7 Amylin
8.7.1 Amylin Comapny Information
8.7.2 Amylin Business Overview
8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Value and Gross Margin (2019-2024)
8.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
8.7.5 Amylin Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
9.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Mode & Process
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
9.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
LIST OF TABLES
Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2019-2024)
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (K Units) & (2019-2024)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Company (2019-2024)
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Company (2019-2024)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Company Manufacturing Base & Headquarters
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Exenatied
Table 18. Major Companies of Liraglutide
Table 19. Major Companies of Lixisenatide
Table 20. Major Companies of Albiglutide
Table 21. Major Companies of Dulaglutide
Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)
Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019-2024) & (K Units)
Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2025-2030) & (K Units)
Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2024)
Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2025-2030)
Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019-2024) & (US$ Million)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2025-2030) & (US$ Million)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2024)
Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2025-2030)
Table 32. Major Companies of Hospital
Table 33. Major Companies of Pharmacy
Table 34. Major Companies of Other
Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)
Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019-2024) & (K Units)
Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2025-2030) & (K Units)
Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2024)
Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2025-2030)
Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019-2024) & (US$ Million)
Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2025-2030) & (US$ Million)
Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2024)
Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2025-2030)
Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2024)
Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2025-2030)
Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2024) & (US$ Million)
Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2019-2024)
Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030) & (US$ Million)
Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2025-2030)
Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2019-2024)
Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2025-2030)
Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2019 VS 2023 VS 2030 (K Units)
Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2019-2024)
Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2025-2030)
Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2024) & (US$ Million)
Table 64. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2019-2024)
Table 65. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2025-2030) & (US$ Million)
Table 66. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2025-2030)
Table 67. Novo Nordisk Company Information
Table 68. Novo Nordisk Business Overview
Table 69. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 70. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 71. Novo Nordisk Recent Development
Table 72. AstraZeneca Company Information
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 75. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 76. AstraZeneca Recent Development
Table 77. Eli Lily Company Information
Table 78. Eli Lily Business Overview
Table 79. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 80. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 81. Eli Lily Recent Development
Table 82. GSK Company Information
Table 83. GSK Business Overview
Table 84. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 85. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 86. GSK Recent Development
Table 87. Sanofi Company Information
Table 88. Sanofi Business Overview
Table 89. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 90. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 91. Sanofi Recent Development
Table 92. Bristol-Myers Squibb Company Information
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 95. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Amylin Company Information
Table 98. Amylin Business Overview
Table 99. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 100. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 101. Amylin Recent Development
Table 102. Key Raw Materials
Table 103. Raw Materials Key Suppliers
Table 104. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 105. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 106. Research Programs/Design for This Report
Table 107. Authors List of This Report
Table 108. Secondary Sources
Table 109. Primary Sources
Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2019-2024)
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Company (K Units) & (2019-2024)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Company (2019-2024)
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) of Company (2019-2024)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Company Manufacturing Base & Headquarters
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company, Product Type & Application
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Exenatied
Table 18. Major Companies of Liraglutide
Table 19. Major Companies of Lixisenatide
Table 20. Major Companies of Albiglutide
Table 21. Major Companies of Dulaglutide
Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)
Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019-2024) & (K Units)
Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2025-2030) & (K Units)
Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2024)
Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2025-2030)
Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019-2024) & (US$ Million)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2025-2030) & (US$ Million)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2024)
Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2025-2030)
Table 32. Major Companies of Hospital
Table 33. Major Companies of Pharmacy
Table 34. Major Companies of Other
Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)
Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019-2024) & (K Units)
Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2025-2030) & (K Units)
Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2024)
Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2025-2030)
Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019-2024) & (US$ Million)
Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2025-2030) & (US$ Million)
Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2024)
Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2025-2030)
Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2024)
Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2025-2030)
Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2019-2024) & (US$ Million)
Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2019-2024)
Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Region (2025-2030) & (US$ Million)
Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region (2025-2030)
Table 55. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2019-2024)
Table 56. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (USD/Unit) by Region (2025-2030)
Table 57. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country: 2019 VS 2023 VS 2030 (K Units)
Table 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
Table 60. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2019-2024)
Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2025-2030)
Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2019-2024) & (US$ Million)
Table 64. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2019-2024)
Table 65. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Country (2025-2030) & (US$ Million)
Table 66. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Market Share by Country (2025-2030)
Table 67. Novo Nordisk Company Information
Table 68. Novo Nordisk Business Overview
Table 69. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 70. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 71. Novo Nordisk Recent Development
Table 72. AstraZeneca Company Information
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 75. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 76. AstraZeneca Recent Development
Table 77. Eli Lily Company Information
Table 78. Eli Lily Business Overview
Table 79. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 80. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 81. Eli Lily Recent Development
Table 82. GSK Company Information
Table 83. GSK Business Overview
Table 84. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 85. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 86. GSK Recent Development
Table 87. Sanofi Company Information
Table 88. Sanofi Business Overview
Table 89. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 90. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 91. Sanofi Recent Development
Table 92. Bristol-Myers Squibb Company Information
Table 93. Bristol-Myers Squibb Business Overview
Table 94. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 95. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 96. Bristol-Myers Squibb Recent Development
Table 97. Amylin Company Information
Table 98. Amylin Business Overview
Table 99. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 100. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
Table 101. Amylin Recent Development
Table 102. Key Raw Materials
Table 103. Raw Materials Key Suppliers
Table 104. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 105. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 106. Research Programs/Design for This Report
Table 107. Authors List of This Report
Table 108. Secondary Sources
Table 109. Primary Sources
LIST OF FIGURES
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2019-2030) & (K Units)
Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Exenatied Picture
Figure 10. Liraglutide Picture
Figure 11. Lixisenatide Picture
Figure 12. Albiglutide Picture
Figure 13. Dulaglutide Picture
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2019 VS 2023 VS 2030
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2030)
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2030)
Figure 20. Hospital Picture
Figure 21. Pharmacy Picture
Figure 22. Other Picture
Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2019 VS 2023 VS 2030
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2030)
Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2019 VS 2023 VS 2030
Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2030)
Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region: 2019 VS 2023 VS 2030
Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 33. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 34. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 35. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 36. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 37. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 39. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 40. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 41. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 43. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2019-2030) & (K Units)
Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Average Price (USD/Unit) & (2019-2030)
Figure 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Exenatied Picture
Figure 10. Liraglutide Picture
Figure 11. Lixisenatide Picture
Figure 12. Albiglutide Picture
Figure 13. Dulaglutide Picture
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2019 VS 2023 VS 2030
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Type (2019-2030)
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type (2019-2030)
Figure 20. Hospital Picture
Figure 21. Pharmacy Picture
Figure 22. Other Picture
Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share 2019 VS 2023 VS 2030
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Volume Share by Application (2019-2030)
Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share 2019 VS 2023 VS 2030
Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application (2019-2030)
Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2019 VS 2023 VS 2030 (K Units)
Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region: 2019 VS 2023 VS 2030
Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 33. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 34. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 35. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 36. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 37. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 39. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 40. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 41. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Country (%), 2023 VS 2030
Figure 43. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. USA Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. Nordic Countries Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Value Growth Rate (2019-2030)
